Irritable Bowel Syndrome Market is estimated to increase at a growth rate of 7.8% CAGR over the forecast period from 2024 to 2030.
The global Irritable Bowel Syndrome Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Others), By Disease (IBS-Constipation, IBS-diarrhea, Mixed), By End-User (Hospitals, Clinics, Homecare Settings).
An Introduction to Irritable Bowel Syndrome Market in 2024
The Irritable Bowel Syndrome (IBS) Market encompasses diagnostic tests, therapeutics, and management strategies for addressing irritable bowel syndrome, a common gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. This market includes medications, dietary supplements, probiotics, and lifestyle modifications aimed at relieving symptoms, managing flare-ups, and improving quality of life for patients with IBS. Irritable bowel syndrome affects a significant portion of the global population, necessitating comprehensive approaches involving medical, dietary, and behavioral interventions. Innovations in the IBS market focus on personalized treatment regimens, targeted therapies, symptom monitoring tools, and patient education initiatives, enhancing outcomes and patient satisfaction in managing this chronic condition.
Irritable Bowel Syndrome Market Competitive Landscape
The global Irritable Bowel Syndrome Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Irritable Bowel Syndrome Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Irritable Bowel Syndrome Industry include- Abbott Laboratories, Allergan, Ardelyx., Astellas Pharma Inc, AstraZeneca Plc, Bausch Health, GlaxoSmithKline plc, Ironwood Pharmaceuticals Inc, Johnson & Johnson Services Inc, LEXICON PHARMACEUTICALS Inc, Mallinckrodt., Novartis AG, Ono Pharmaceutical Co. Ltd, Pfizer Inc, Salix Pharmaceuticals, Sebela Pharmaceuticals Inc, Synergy Pharmaceuticals Inc, Synthetic Biologics Inc, Takeda Pharmaceutical Co. Ltd.
Irritable Bowel Syndrome (IBS) Market Trend: Growing Research and Development of Targeted Therapies
A significant trend in the market for irritable bowel syndrome (IBS) is the growing research and development of targeted therapies for the management of IBS symptoms and underlying pathophysiology. IBS is a complex gastrointestinal disorder characterized by abdominal pain, bloating, diarrhea, and/or constipation, affecting millions of individuals worldwide. Recent advancements in understanding the pathophysiology of IBS, including alterations in gut microbiota, intestinal motility, visceral hypersensitivity, and immune activation, have led to the identification of novel therapeutic targets and treatment approaches. This trend encompasses the development of pharmacological agents, probiotics, dietary supplements, and behavioral therapies that target specific mechanisms involved in IBS pathogenesis, aiming to provide more effective and personalized treatment options for patients with IBS.
Irritable Bowel Syndrome (IBS) Market Driver: Rising Prevalence of Functional Gastrointestinal Disorders
The primary driver of the IBS market is the rising prevalence of functional gastrointestinal disorders, including IBS, globally. IBS is one of the most common functional GI disorders, affecting up to 10-15% of the world's population, with a higher prevalence in women and individuals under the age of 50. Factors such as stress, diet, altered gut microbiota, and genetic predisposition contribute to the development and exacerbation of IBS symptoms. Additionally, the increasing awareness of IBS among healthcare providers and patients, improved diagnostic criteria, and advancements in diagnostic testing technologies have led to higher rates of diagnosis and healthcare-seeking behavior among individuals with IBS symptoms. As the global burden of functional GI disorders continues to rise, there is growing demand for effective and evidence-based therapies to manage IBS symptoms, driving market growth for IBS treatments and management strategies.
Irritable Bowel Syndrome (IBS) Market Opportunity: Integration of Digital Health Technologies and Patient Support Services
An opportunity in the IBS market lies in the integration of digital health technologies and patient support services to enhance disease management, patient education, and treatment adherence. Digital health solutions, such as mobile applications, telemedicine platforms, and wearable devices, offer opportunities to monitor symptoms, track dietary habits, and communicate with healthcare providers remotely, empowering patients to take an active role in managing their IBS and optimizing treatment outcomes. Additionally, patient support services, such as IBS-focused counseling, dietary guidance, and lifestyle interventions, can complement pharmacological therapies and improve patient compliance with treatment regimens. Manufacturers and healthcare providers can capitalize on this opportunity by developing user-friendly digital tools, educational resources, and patient-centered support programs that address the multifaceted needs of individuals with IBS, ultimately enhancing patient engagement, quality of life, and long-term management of IBS symptoms.
Irritable Bowel Syndrome Market Share Analysis: Linaclotide is the fastest growing market segment over the forecast period to 2030
Among the various drugs used for treating Irritable Bowel Syndrome (IBS), Linaclotide is experiencing the fastest growth. Linaclotide is a medication classified as a guanylate cyclase-C agonist, primarily indicated for the treatment of IBS with constipation (IBS-C) and chronic idiopathic constipation (CIC). It works by increasing fluid secretion in the intestine and accelerating gastrointestinal transit, thereby alleviating symptoms such as abdominal pain, bloating, and constipation. The rapid growth of Linaclotide can be attributed to several factors, including its proven efficacy in clinical trials, its favorable safety profile, and the increasing prevalence of IBS-related disorders worldwide. Additionally, healthcare providers are increasingly prescribing Linaclotide as a first-line treatment option for patients with IBS-C due to its effectiveness in symptom relief and improvement in quality of life. Furthermore, the availability of Linaclotide through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, has contributed to its widespread adoption and rapid growth in the market. As awareness about IBS and its treatment options continues to increase, along with the expanding patient pool seeking relief from IBS symptoms, Linaclotide is anticipated to maintain its position as the fastest-growing drug in the management of Irritable Bowel Syndrome.
Irritable Bowel Syndrome Market Segmentation
By Drug
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Alosetron
Others
By Disease
IBS-Constipation
IBS-diarrhea
Mixed
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By End-User
Hospitals
Clinics
Homecare Settings
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Irritable Bowel Syndrome Companies
Abbott Laboratories
Allergan
Ardelyx.
Astellas Pharma Inc
AstraZeneca Plc
Bausch Health
GlaxoSmithKline plc
Ironwood Pharmaceuticals Inc
Johnson & Johnson Services Inc
LEXICON PHARMACEUTICALS Inc
Mallinckrodt.
Novartis AG
Ono Pharmaceutical Co. Ltd
Pfizer Inc
Salix Pharmaceuticals
Sebela Pharmaceuticals Inc
Synergy Pharmaceuticals Inc
Synthetic Biologics Inc
Takeda Pharmaceutical Co. Ltd
* List not Exhaustive
Reasons to Buy the Irritable Bowel Syndrome Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Irritable Bowel Syndrome Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Irritable Bowel Syndrome Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Irritable Bowel Syndrome Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Irritable Bowel Syndrome Market Size Outlook, $ Million, 2021 to 2030
3.2 Irritable Bowel Syndrome Market Outlook by Type, $ Million, 2021 to 2030
3.3 Irritable Bowel Syndrome Market Outlook by Product, $ Million, 2021 to 2030
3.4 Irritable Bowel Syndrome Market Outlook by Application, $ Million, 2021 to 2030
3.5 Irritable Bowel Syndrome Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Irritable Bowel Syndrome Industry
4.2 Key Market Trends in Irritable Bowel Syndrome Industry
4.3 Potential Opportunities in Irritable Bowel Syndrome Industry
4.4 Key Challenges in Irritable Bowel Syndrome Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Irritable Bowel Syndrome Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Irritable Bowel Syndrome Market Outlook by Segments
7.1 Irritable Bowel Syndrome Market Outlook by Segments, $ Million, 2021- 2030
By Drug
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Alosetron
Others
By Disease
IBS-Constipation
IBS-diarrhea
Mixed
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By End-User
Hospitals
Clinics
Homecare Settings
8 North America Irritable Bowel Syndrome Market Analysis and Outlook To 2030
8.1 Introduction to North America Irritable Bowel Syndrome Markets in 2024
8.2 North America Irritable Bowel Syndrome Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Irritable Bowel Syndrome Market size Outlook by Segments, 2021-2030
By Drug
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Alosetron
Others
By Disease
IBS-Constipation
IBS-diarrhea
Mixed
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By End-User
Hospitals
Clinics
Homecare Settings
9 Europe Irritable Bowel Syndrome Market Analysis and Outlook To 2030
9.1 Introduction to Europe Irritable Bowel Syndrome Markets in 2024
9.2 Europe Irritable Bowel Syndrome Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Irritable Bowel Syndrome Market Size Outlook by Segments, 2021-2030
By Drug
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Alosetron
Others
By Disease
IBS-Constipation
IBS-diarrhea
Mixed
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By End-User
Hospitals
Clinics
Homecare Settings
10 Asia Pacific Irritable Bowel Syndrome Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Irritable Bowel Syndrome Markets in 2024
10.2 Asia Pacific Irritable Bowel Syndrome Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Irritable Bowel Syndrome Market size Outlook by Segments, 2021-2030
By Drug
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Alosetron
Others
By Disease
IBS-Constipation
IBS-diarrhea
Mixed
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By End-User
Hospitals
Clinics
Homecare Settings
11 South America Irritable Bowel Syndrome Market Analysis and Outlook To 2030
11.1 Introduction to South America Irritable Bowel Syndrome Markets in 2024
11.2 South America Irritable Bowel Syndrome Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Irritable Bowel Syndrome Market size Outlook by Segments, 2021-2030
By Drug
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Alosetron
Others
By Disease
IBS-Constipation
IBS-diarrhea
Mixed
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By End-User
Hospitals
Clinics
Homecare Settings
12 Middle East and Africa Irritable Bowel Syndrome Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Irritable Bowel Syndrome Markets in 2024
12.2 Middle East and Africa Irritable Bowel Syndrome Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Irritable Bowel Syndrome Market size Outlook by Segments, 2021-2030
By Drug
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Alosetron
Others
By Disease
IBS-Constipation
IBS-diarrhea
Mixed
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By End-User
Hospitals
Clinics
Homecare Settings
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Allergan
Ardelyx.
Astellas Pharma Inc
AstraZeneca Plc
Bausch Health
GlaxoSmithKline plc
Ironwood Pharmaceuticals Inc
Johnson & Johnson Services Inc
LEXICON PHARMACEUTICALS Inc
Mallinckrodt.
Novartis AG
Ono Pharmaceutical Co. Ltd
Pfizer Inc
Salix Pharmaceuticals
Sebela Pharmaceuticals Inc
Synergy Pharmaceuticals Inc
Synthetic Biologics Inc
Takeda Pharmaceutical Co. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
